ArticleiScience2026
Association between adipokine and metabolic dysfunction-related fatty liver disease in plateau-dwelling populations.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Pathophysiological Interrelationship Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Cardiovascular Disease.Antioxidants (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous research on the relationship between adipokines and metabolic dysfunction-associated steatotic liver disease (MASLD) has predominantly focused on low-altitude populations, despite the well-documented impact of environmental stressors on adipokine expression. This study sought to explore the relationship between adipokines and MASLD across various metabolic subtypes and to develop a predictive model for MASLD screening in high-altitude regions. This study included 750 indigenous plateau residents from the China Multi-Ethnic Cohort (CMEC). Logistic regression analyses were conducted to examine the associations of leptin, A-fatty acid binding protein, and visfatin with MASLD. Among the three adipokines, only leptin demonstrated a significant association with MASLD in both obesity and non-obesity populations. The predictive model based on leptin yielded an area under the curve of 0.86 (95% CI: 0.83-0.90). This study provides evidence that leptin serves as a diagnostic biomarker for identifying MASLD among indigenous plateau populations, applicable to both obesity and non-obesity individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.